Overview
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
Eligibility
Inclusion Criteria:
- Confirmed diagnosis of retinitis pigmentosa
- Bare light perception in at least one eye
Exclusion Criteria:
- Prior receipt of any AAV gene therapy product
- Large amplitude nystagmus